NOV. 21. 2003 | 3:43 PM

OBLON SPIVAK

RECEIVED
NO. 732 CENTRAL FAX CENTER

NOV 2 1 2003

OFFICIAL

	by certify f hown belo	nat this paper is being facsimile transmitted to the U.S. Patent and T	Yademark Office on the
Date:	Novemb	er 21, 2003 Signature:	
		Attorney	
To:	Examiner	Chunduru Telephone Number: 703-305-1004	
	Group Ar	Unit: 1637	
	Facsimile	No.: 703-3-11 763 872-9306	
From:	Daniel J.	Pereira Registration No.: 45,518	
Telepl	none Numl	er: 703-413-6560	
Date:	Novembe	21, 2003	
RE:	U.S. Appl	cation Scrial Number: 09/622,583	
	Filed: G	ctober 13, 2000	
	Attorney I	Oocket Number: 195707US0PCT	
TOTA	L NUME	ER OF PAGES INCLUDING THIS PAGE:6	
	į	COMMENTS	

In the event that any fccs are due, including any fees required under 37 CFR 1.136 for any necessary

Extension of Time to make the filing of the attached documents timely, please charge the required fees to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby

PAGE 1/6 \* RCVD AT 11/21/2003 3:44:35 PM [Eastern Standard Time] \* SVR:USPTO-EFXRF-1/1 \* DNIS:8729306 \* CSID:7034132220 \* DURATION (mm-ss):01-58

Attached is the revised amendment we discussed. Please call if you require any additional information.

made under 37 CFR 1.136 for the necessary extension of time.

Thank you.

NOV 2 1 2003

OFFICIAL

DOCKET NO: 195707US0PCT

## IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF

EDGARDO D. CAROSELLA, ET AL.

: EXAMINER: CHUNDURU, S.

SERIAL NO: 09/622,583

FILED: OCTOBER 13, 2000

: GROUP ART UNIT: 1637

FOR: METHOD FOR SELECTING
TUMOURS EXPRESSING HLA-G WHICH
ARE SENSITIVE TO ANTICANCER
TREATMENT, AND USES THEREOF

## **AMENDMENT**

COMMİSSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

In response to the Official Action mailed February 27, 2003, and concurrent with the Request for Continued Examination filed herewith, Applicants request reconsideration and allowance of this application.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 5 of this paper.